21 completed, 5 recruiting, 5 terminated, 3 unknown. 38 Phase 3, 9 Phase 2.
Follow Thinness: new trials by email Literature Review of Thinness trials Research Report on Thinness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug, Placebo - Cachexia; Cancer, Cachexia | Phase 2 / Phase 3 | Not yet recruiting | AVEO Pharmaceuticals, Inc. | 950 | 2026-11-01 | 2026-10-28 |
| Micronutrient Enhancement for Development and Health in Adolescents - The MEDHA Study Iron (60 mg)- folic acid (400 ug) [IFA], Multiple micronutrient supplement [MMS], Multiple micronutrient supplement Plus [MMS+] - Neurodevelopment Outcome, Linear Growth | Phase 3 | Recruiting | Johns Hopkins Bloomberg School of Public Health | 3000 | 2026-09-27 | 2026-10-09 |
| Visugromab in Cachexia International Trial Visugromab (CTL-002), Placebo - Cancer-associated Cachexia | Phase 2 / Phase 3 | Recruiting | CatalYm GmbH | 518 | 2026-04-16 | 2026-11-02 |
| Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma Nanocrystalline Megestrol Acetate, Standard Antitumor Therapy - Cachexia, Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 68 | 2026-01-10 | 2026-01-21 |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue ponsegromab, placebo - Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Pfizer | 982 | 2025-10-03 | 2026-10-14 |
| Alternative RUTFs for Treatment of Child Wasting Soy-based RUTF, Soy-maize-sorghum-based RUTF, Standard RUTF - Severe Acute Malnutrition, Moderate Acute Malnutrition | Phase 3 | Completed | International Food Policy Research Institute | 2269 | 2025-03-21 | 2026-05-13 |
| Olanzapine for Cancer Related Anorexia-cachexia Syndrome Olanzapine 2.5 MG, Olanzapine 5 MG, Placebo - Anorexia, Cachexia | Phase 3 | Unknown | Mahidol University | 138 | 2024-01-22 | 2024-07-24 |
| Impact of Bi-26 Supplementation on Weight Gain in Underweight Infants B. infantis Bi-26, Placebo - Underweight, Paediatrics | Phase 3 | Terminated | Gates Medical Research Institute | 40 | 2023-07-03 | 2025-03-04 |
| Lactoferrin and Lysozyme Supplementation for Long-term Diarrhea Sequelae Lactoferrin, Lysozyme, Lactoferrin + Lysozyme - Diarrhea, Wasting | Phase 3 | Recruiting | University of Washington | 600 | 2023-03-10 | 2025-09-11 |
| ComPAS Low-WAZ RCT Mali Simplified dose of ready-to-use therapeutic food (RUTF), Standard dose of ready-to-use therapeutic food (RUTF), No nutritional treatment - Acute Malnutrition in Infancy, Acute Malnutrition in Childhood | Phase 2 / Phase 3 | Unknown | International Rescue Committee | 1500 | 2022-09-01 | 2024-01-03 |
| Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia PPP011, Placebo - Cannabis Use, Cachexia; Cancer | Phase 3 | Suspended | Tetra Bio-Pharma | 334 | 2022-07-01 | 2021-02-05 |
| Management of Shock in Children With SAM or Severe Underweight and Diarrhea Blood and Dopamine, Blood and adrenaline - Shock Hypovolemic, Shock, Septic | Phase 3 | Recruiting | International Centre for Diarrhoeal Disease Research, Bangladesh | 135 | 2021-08-17 | 2025-04-16 |
| A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2 anamorelin HCl, Placebo Oral Tablet - Cachexia; Cancer, Non Small Cell Lung Cancer | Phase 3 | Completed | Helsinn Healthcare SA | 318 | 2019-05-06 | 2026-10-06 |
| A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1 Anamorelin Hydrochloride, Placebo Oral Tablet - Cachexia; Cancer, Non Small Cell Lung Cancer | Phase 3 | Completed | Helsinn Healthcare SA | 318 | 2019-03-05 | 2026-10-06 |
| Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy standard care, nutritional supplements and advice, home-based self-assisted exercise program - Cachexia, Neoplasms | Phase 3 | Completed | Norwegian University of Science and Technology | 221 | 2015-04-01 | 2025-08-29 |
| Reformulated F75 Milk to Treat Severe Acute Malnutrition Standard F75 Milk, Modified F75 Milk - Malnutrition, Diarrhoea | Phase 2 / Phase 3 | Completed | University of Oxford | 842 | 2014-12-01 | 2016-04-14 |
| Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients Nabilone, Placebo - Non-Small Cell Lung Cancer, Anorexia | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cancerologia de Mexico | 78 | 2014-12-01 | 2016-08-31 |
| Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis Interferon beta-1a, Fingolimod, Placebo capsule - Multiple Sclerosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 240 | 2013-07-26 | 2026-08-10 |
| Complementary Food Supplements for Reducing Childhood Undernutrition Wheat Soy Blend (WSB++), Chickpea based complementary food supplement, Rice based complementary food supplement - Stunting, Wasting | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 5449 | 2012-09-01 | 2018-08-24 |
| Soy-Ready to Use Therapeutic Food (RUTF) in Severely Malnourished Children Soy-based RUTF (in double blind design) - Severe Acute Malnutrition, Severe Wasting | Phase 2 / Phase 3 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 260 | 2012-07-01 | 2017-09-25 |
Showing 20 of 38. Sign in to see all of them.
Cachexia (34) · Anorexia (16) · Carcinoma, Non-Small-Cell Lung (10) · Neoplasms (9) · Weight Loss (7) · Body Weight (4) · Lung Neoplasms (4) · Malnutrition (4) · Severe Acute Malnutrition (4) · Growth Disorders (3) · Body Weight Changes (2) · Diarrhea (2) · Fatigue (2) · Kwashiorkor (2)
Pathological Conditions, Signs and Symptoms (38) · Signs and Symptoms (38) · Body Weight (34) · Body Weight Changes (32) · Weight Loss (27) · Signs and Symptoms, Digestive (19) · Neoplasms by Site (17) · Lung Diseases (12) · Neoplasms (12) · Respiratory Tract Diseases (12) · Respiratory Tract Neoplasms (12) · Thoracic Neoplasms (12) · Bronchial Neoplasms (10) · Carcinoma, Bronchogenic (10)
Megestrol Acetate (6) · Olanzapine (2) · Blood Specimen Collection (1) · Caseins (1) · Counseling (1) · Creatine (1) · Cyproheptadine (1) · Dietary Supplements (1) · Docetaxel (1) · Dopamine (1) · Eicosapentaenoic Acid (1) · Epinephrine (1) · Etanercept (1) · Fingolimod Hydrochloride (1) · Folic Acid (1)
Alliance for Clinical Trials in Oncology (3) · Helsinn Therapeutics (U.S.), Inc (3) · Helsinn Healthcare SA (2) · International Centre for Diarrhoeal Disease Research, Bangladesh (2) · Johns Hopkins Bloomberg School of Public Health (2) · Par Pharmaceutical, Inc. (2) · University of Oxford (2) · Wake Forest University Health Sciences (2) · AVEO Pharmaceuticals, Inc. (1) · Bristol-Myers Squibb (1) · CatalYm GmbH (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Charite University, Berlin, Germany (1) · Gates Medical Research Institute (1) · Immunotec Inc. (1)
United States (21) · Canada (9) · Germany (7) · Poland (7) · Italy (6) · Russia (6) · Australia (5) · France (5) · Spain (5) · United Kingdom (5) · Bangladesh (4) · Belgium (4) · Bulgaria (4) · Hungary (4) · Romania (4)
Aminah Jatoi, MD (4) · Lynn D Kramer, MD (2) · Parul Christian, DrPH (2) · Tahmeed Ahmed, PhD (2) · Abu Ahmed Shamim, MS (1) · Alain B Labrique, PhD (1) · Bart Frizzell, MD (1) · Britta Schumacher, PhD (1) · Edward G. Shaw, MD (1) · Hasmot Ali, MPH (1) · James A Berkley (1) · James A Berkley, FRCPCH (1) · Janet Bull, MD (1) · Jeffrey P. Krischer, PhD (1)
PMID 28472437, PMID 26906526, PMID 39992021, PMID 10371570, PMID 11786587, PMID 12457271, PMID 15197210, PMID 15778874, PMID 15857739, PMID 1632474, PMID 16376734, PMID 16408219, PMID 1666930, PMID 16849753, PMID 17589370, PMID 17674351, PMID 18293016, PMID 18402303, PMID 19593244, PMID 19665818, PMID 21343383, PMID 21615299, PMID 21627690, PMID 23439759, PMID 23496872, PMID 24196006, PMID 24661049, PMID 25351456, PMID 26323041, PMID 26440279, PMID 27265353, PMID 27673385, PMID 27680994, PMID 28144779, PMID 28316439, PMID 28509730, PMID 28644348, PMID 29178404, PMID 29318195, PMID 29550881, PMID 29635501, PMID 30065491, PMID 30184222, PMID 30207920, PMID 30266874, PMID 30807589, PMID 31037340, PMID 31467033, PMID 31775877, PMID 31821418
2018 (2), 2025 (1), R01HD103642 (1), U10CA081920 (1)